Molecule Holdings Inc.

OTC: EVRRF · Healthcare · Drug Manufacturers - Specialty & Generic

Canadian filerHQ Lansdowne, ONReports USD

#819 of 1,394 Healthcare companies by revenuetop-decile growth

EA Score

——

FH —DQ —GM —SS 29

v0.1 · 5/100 weight · pillars only

↑ revenue growth (YoY), Piotroski F · ↓ balance-sheet leverage, disclosure history

Methodology →

Revenue TTM

$1.3M

Rev growth YoY (TTM)

+6.4%

Net income (FY)

-$3.5M

Employees

Market cap

$626.1k

Financials — latest annual

SEC EDGAR · USD-normalized

ConceptUSDNativeFY

Revenue$1.5M2.0M CAD2022

Net income-$3.5M-4.5M CAD2022

Operating income-$3.0M-3.9M CAD2022

Total assets$2.9M3.9M CAD2022

Liabilities$5.6M7.6M CAD2022

Equity-$2.7M-3.7M CAD2022

Revenue trend

FY2019 – FY2022 · USD

FY19

FY20

$362.0k

FY21

$1.5M

FY22

Revenue by segment

No segmentation disclosed for this filer. n/a

The read

Molecule Holdings Inc. booked $1.5M in FY2022 revenue, growing 322% year over year — faster than 92% of Healthcare companies we track, at a -230.8% net margin.

Peers · Healthcare

Concord Medical Services Holdings Limited58C ChitogenX Inc.——StageZero Life Sciences Ltd.——Pharmagreen Biotech Inc.——

Key facts

CEODavid Reingold

SectorHealthcare

IndustryDrug Manufacturers - Specialty & Generic

HeadquartersLansdowne, ON

ExchangeOTC: EVRRF

Employees13

IPO date2020-09-22

Latest filings

No filings loaded — no CIK (non-SEC filer).

Financials: SEC EDGAR (XBRL), USD-normalized per IAS 21 · TTM/quarterly + segments: FMP from filed disclosures · Filings: EDGAR submissions. County headcount and EA Score are in progress — see docs/DATA_GAPS.md.